08/10/01

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:19:10 ON 10 AUG 2001

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 12:19:58 ON 10 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 9 AUG 2001 HIGHEST RN 350981-09-8
DICTIONARY FILE UPDATES: 9 AUG 2001 HIGHEST RN 350981-09-8

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> e arginine/cn

E1 1 ARGININANILIDE, N.ALPHA.,N.OMEGA.,N.OMEGA.-TRIS(PHENYLCARBAMOYL)-, L-/CN
E2 1 ARGININANILIDE, N2-BENZOYL-/CN
E3 2 --> ARGININE/CN
E4 1 ARGININE .BETA.-NAPHTHYLAMIDE/CN
E5 1 ARGININE 2,2,2-TRICHLOROETHYL ESTER/CN
E6 1 ARGININE 2-MONOOXYGENASE/CN
E7 1 ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTI)/CN
E8 1 ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTJ)/CN
E9 1 ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (ESCHERICHIA COLI STRAIN O157:H7 GENE ECS0943)/CN
E10 1 ARGININE 3RD TRANSPORT SYSTEM PERIPLASMIC BINDING PROTEIN (ESCHERICHIA COLI STRAIN O157:H7 GENE ECS0946)/CN
E11 1 ARGININE 3RD TRANSPORT SYSTEM PERMEASE PROTEIN (ESCHERICHIA COLI O157:H7 STRAIN EDL933 GENE ARTM)/CN
E12 1 ARGININE 3RD TRANSPORT SYSTEM PERMEASE PROTEIN (ESCHERICHIA

```
=> s e3

L1            2 ARGININE/CN

=> file ca, uspatfull, medline, biosis, toxlit, toxline

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     4.11       4.26

FILE 'CA' ENTERED AT 12:20:41 ON 10 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:20:41 ON 10 AUG 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:20:41 ON 10 AUG 2001

FILE 'BIOSIS' ENTERED AT 12:20:41 ON 10 AUG 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'TOXLIT' ENTERED AT 12:20:41 ON 10 AUG 2001

FILE 'TOXLINE' ENTERED AT 12:20:41 ON 10 AUG 2001

=> s l1

L2        80894 L1

=> s controlled(3a)releas####

L3        51312 CONTROLLED(3A) RELEAS####

=> s sustained(3a)releas####

L4        48644 SUSTAINED(3A) RELEAS####

=> s l3 or l4

L5        93029 L3 OR L4

=> s extended(3a)release####

L6         6123 EXTENDED(3A) RELEASE####

=> s l6 or l5

L7        97440 L6 OR L5

=> s l7 and l2

L8          247 L7 AND L2

=> dup remove l8

PROCESSING COMPLETED FOR L8
L9           196 DUP REMOVE L8 (51 DUPLICATES REMOVED)

=> s tablet#

L10      216886 TABLET#
```

```
=> s l10 and l9

L11          61 L10 AND L9

=> s sustained(5a)matrix

L12        2061 SUSTAINED(5A) MATRIX

=> s l12 and l11

L13           0 L12 AND L11

=> s l12 and l8

L14           4 L12 AND L8

=> s l12 and l2

L15           8 L12 AND L2

=> s l14 or l15

L16           8 L14 OR L15

=> dup remove l16

PROCESSING COMPLETED FOR L16
L17           8 DUP REMOVE L16 (0 DUPLICATES REMOVED)

=> d l17 1-8 bib,ab


L17  ANSWER 1 OF 8  USPATFULL
AN      2001:111858  USPATFULL
TI      Methods for increasing vascularization and promoting wound healing
IN      Usala, Anton-Lewis, 237 Buckingham Dr., Winterville, NC, United States
        28590
PI      US 6261587          B1   20010717
AI      US 1999-337959           19990622 (9)
RLI     Continuation-in-part of Ser. No. US 1998-113437, filed on 10 Jul 1998
DT      Utility
FS      GRANTED
EXNAM   Primary Examiner: Azpuru, Carlos A.
LREP    Alston & Bird LLP
CLMN    Number of Claims: 57
ECL     Exemplary Claim: 1
DRWN    4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention provides a method of stimulating vascularization
        at a site in a mammal, said method comprising contacting said site with
        a matrix comprising gelatin and a nitric oxide inhibitor. The gelatin
is
        preferably denatured collagen. The nitric oxide inhibitor may be a
        sulfonated moiety. The inhibitor may be an L-arginine analog, such as
        aminoguanidine, N-monoethyl L-arginine, N-nitro-L-arginine and
        D-arginine. The matrix may further comprise a nitric oxide scavenger,
        such as dextran, heparin, cysteine and cystine.

L17  ANSWER 2 OF 8  USPATFULL
AN      2001:97890  USPATFULL
TI      Antiangiogenic peptides and methods for inhibiting angiogenesis
IN      Davidson, Donald J., Gurnee, IL, United States
PA      Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
```

PI US 6251867 B1 20010626
AI US 1998-132154 19980811 (9)
RLI Continuation of Ser. No. US 1998-132154, filed on 11 Aug 1998 And Ser. No. US 1997-832087, filed on 3 Apr 1997 Continuation-in-part of Ser. No.
US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DT Utility
FS GRANTED
EXNAM Primary Examiner: Hendricks, Keith D.; Assistant Examiner: Stole, Einar
LREP Steele, Gregory W., Casuto, Dianne
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2101
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

L17 ANSWER 3 OF 8 USPATFULL
AN 2001:71117 USPATFULL
TI Medium and matrix for long-term proliferation of cells
IN Usala, Anton-Lewis, 237 Buckingham Dr., Winterville, NC, United States 28590
Klann, Richard Chris, 239 E. Main St., Washington, NC, United States 27889
PI US 6231881 B1 20010515
AI US 1998-113437 19980710 (9)
RLI Continuation-in-part of Ser. No. US 1995-568482, filed on 7 Dec 1995, now patented, Pat. No. US 5834005 Continuation-in-part of Ser. No. US 1994-300429, filed on 2 Sep 1994, now abandoned Continuation-in-part of Ser. No. US 1992-841973, filed on 24 Feb 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Alston & Bird LLP
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1020
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A cell culture medium and hydrogel matrix for long term storage and proliferation of cells is provided. The cell culture medium and hydrogel
matrix include an effective amount of polar amino acids, the polar amino
acids selected from the group consisting of arginine, lysine, histidine,
glutamic acid, and aspartic acid. The cell culture medium comprises about 5 to about 150 mM of polar amino acids. The hydrogel matrix comprises about 3 to about 150 mM of polar amino acids. Arginine and glutamic acid are preferably supplemented in the cell culture medium. Arginine, lysine, and glutamic acid are preferably supplemented in the hydrogel matrix. A method of maintaining viability and functioning of a transplant is also provided. The method of maintaining viability of a transplant includes encapsulating the cells in a hydrogel matrix and injecting the encapsulated cells into the host organism. The matrix of the present invention may also be used to promote vascularization in a transplant site prior to injection of cells.

L17 ANSWER 4 OF 8 USPATFULL
AN 1999:132781 USPATFULL
TI Antiangiogenic peptides and methods for inhibiting angiogenesis
IN Davidson, Donald J., Gurnee, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

PI US 5972896 19991026
AI US 1998-131995 19980811 (9)
RLI Continuation of Ser. No. US 1997-832087, filed on 3 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-643219, filed on 3 May 1996, now patented, Pat. No. US 5801146
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Stole, Einar
LREP Steele, Gregory W., Casuto, Dianne
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 2444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian kringle 5 fragments are disclosed as a compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

L17 ANSWER 5 OF 8 USPATFULL
AN 1998:134650 USPATFULL
TI Bioartificial devices and cellular matrices therefor
IN Usala, Anton-Lewis, Winterville, NC, United States
PA Encelle, Inc., United States (U.S. corporation)
PI US 5830492 19981103
AI US 1995-568694 19951207 (8)
RLI Continuation-in-part of Ser. No. US 1994-300429, filed on 2 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-841973, filed on 24 Feb 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Azpuru, Carlos
LREP Alston & Bird, LLP
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A device for the effective release of cellular moieties, including hormones, wherein a matrix containing a hormone producing cellular moiety is encapsulated with a non-immunogenic polymeric material of poly-para-xylylene or other aromatic based moiety having a membrane portion with a porosity blocking passage therethrough of immunogenic agents and permitting passage therethrough of effective nutrients for said cellular moiety and the hormone produced thereby, an improved matrix for the storage, manufacture, functional testing, and viral infection testing of cellular moieties wherein a collagen based hydrogel
is processed to present a liquid phase at host temperature and functions
as a substrate for cellular attachment with additives effective for limiting thermal and pressure trauma, and an improved method for the harvesting tissue from organs.

L17 ANSWER 6 OF 8 USPATFULL
AN 1998:127929 USPATFULL
TI Bioartificial devices and cellular matrices therefor
IN Usala, Anton-Lewis, Winterville, NC, United States
PA Encelle, Inc., United States (U.S. corporation)
PI US 5824331 19981020
AI US 1995-568503 19951207 (8)
RLI Continuation-in-part of Ser. No. US 1994-300429, filed on 2 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1992-841973, filed on 24 Feb 1992, now abandoned
DT Utility
FS Granted

EXNAM Primary Examiner: Azpuru, Carlos
LREP Alston & Bird, LLP
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 37 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 1549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A device for the effective release of cellular moieties, including hormones, wherein a matrix containing a hormone producing cellular moiety is encapsulated with a nonimmunogenic polymeric material of poly-para-xylylene or other aromatic based polymeric moiety having a membrane portion with a porosity blocking passage therethrough of immunogenic agents and permitting passage therethrough of effective nutrients for said cellular moiety and the hormone produced thereby, an improved matrix for the storage, manufacture, functional testing, and viral infection testing of cellular moieties wherein a collagen based hydrogel is processed to present a liquid phase at host temperature and functions as a substrate for cellular attachment with additives effective for limiting thermal and pressure trauma, and an improved method for the harvesting tissue from organs.

L17 ANSWER 7 OF 8 USPATFULL
AN 1998:104717 USPATFULL
TI Compound and method for inhibiting angiogenesis
IN Davidson, Donald J., Gurnee, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5801146 19980901
AI US 1996-643219 19960503 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.; Assistant Examiner: Stole, Einar
LREP Steele, Gregory W., Casuto, Dianne
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 1510
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Mammalian kringle 5 is disclosed as a compound for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed.

L17 ANSWER 8 OF 8 CA COPYRIGHT 2001 ACS
AN 106:38499 CA
TI Antitumor depot
IN Wahlig, Helmut; Dingeldein, Elvira
PA Merck Patent G.m.b.H., Fed. Rep. Ger.
SO Ger. Offen., 16 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3513938	A1	19861023	DE 1985-3513938	19850418
	AU 8654656	A1	19861023	AU 1986-54656	19860312
	AU 587432	B2	19890817		
	EP 202445	A2	19861126	EP 1986-104723	19860407
	EP 202445	A3	19870812		
	EP 202445	B1	19910220		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 60904	E	19910315	AT 1986-104723	19860407
	CA 1282330	A1	19910402	CA 1986-506775	19860416
	JP 61243015	A2	19861029	JP 1986-87256	19860417
	HU 44170	A2	19880229	HU 1986-1608	19860417
	HU 198383	B	19891030		

	ES 554090	A1	19880316	ES 1986-554090	19860417
	ZA 8602947	A	19870930	ZA 1986-2947	19860418
PRAI	DE 1985-3513938		19850418		
	EP 1986-104723		19860407		

AB An implantable **sustained-release** depot for the treatment of tumor contains a cytostatic agent and an amino acid (particle size <125 .mu.m) incorporated into polyacrylate and/or polymethacrylate. Thus, 39.2 g bead poly(Me acrylate-Me methacrylate), contg. 0.5% Bz2O2 at traces of chlorophyll, was mixed with 0.8 g L-arginine, 0.5 g methotrexate and 20 mL Me methacrylate, contg. 0.7% dimethyl-p-toluidine and 0.006% hydroquinone, to give an antitumor implant.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.60	35.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.56	-0.56

STN INTERNATIONAL LOGOFF AT 12:25:31 ON 10 AUG 2001